EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$2.79
-0.03 (-1.06%)
▼
5d:
-3.46%
30d:
-18.18%
90d:
-37.93%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 20, 2026
15d
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EVAX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: EVAX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $2.79, which is considered oversold relative to its 30-day fair value range of $2.89 to $3.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 69.8) compared to its historical average (84.6). Remarkably, the market is currently pricing in an annual earnings decline of 6.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVAX is in a strong downtrend. The price is currently testing key support at $2.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+303.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EVAX is in a strong downtrend. The price is currently testing key support at $2.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+303.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.89 -
$3.23
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 303.2% below Wall St target ($11.25)
Trading Range Analysis
30-Day Trading Range
$2.89 -
$3.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.77
Resistance Level
$3.15
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
69.75
Wall Street Target
$11.25
(+303.2%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Discount vs History
-6.2% cheaper
PE vs Historical
69.8 vs 84.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.2%
(market-implied from PE analysis)
1-Year Target
$2.62
(-6%)
2-Year Target
$2.45
(-12%)
3-Year Target
$2.30
(-18%)
3-Yr Target (if PE normalizes)
(PE: 70→85)
$2.79
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 69.8 to 84.6
Stabilization Target:
$3.38
(+21.3%)
PE Expansion Potential:
+21.3%
Share & Embed Analysis
Last updated: August 04, 2026 8:25 AM ET
Data refreshes hourly during market hours. Next update: 9:25 AM
Data refreshes hourly during market hours. Next update: 9:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 52 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 54 HOLD |